Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s [Yahoo! Finance]
Halozyme Therapeutics, Inc. (HALO)
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
halozyme.com/investors/default.aspx
Company Research
Source: Yahoo! Finance
technologies with IP into the mid-2040s and adding hyperconcentration capabilities (up to ~500 mg/mL) to cut injection volumes and enable autoinjector use; Hypercon is expected to be clinic-ready in 2026 and Surf Bio by end-2027/early-2028, with two Hypercon Phase I starts targeted by end-2026. Raised 2026 guidance and strong 2025 results: Preliminary 2025 revenue came in at $1.385–$1.40 billion (royalties $865–$870 million), and Halozyme raised 2026 guidance to $1.71–$1.81 billion total revenue, $1.13–$1.17 billion in royalties, and non-GAAP diluted EPS of $7.75–$8.25, citing royalty growth from key partners as the main driver. Updated 2028 roadmap and profit targets: Management now expects 2028 total revenue above $2 billion, royalty revenue of $1.46–$1.51 billion (26%–28% CAGR from 2024), non-GAAP EPS of $10.50–$11.10, and ambitious margin/FCF goals (gross margin 80%, operating margin 60%, and free cash flow 70% of EBITDA for 2026–2028). Interested in Halozyme Therapeutics, I
Show less
Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HALO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HALO alerts
High impacting Halozyme Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HALO
News
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
- Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth [Seeking Alpha]Seeking Alpha
- What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders [Yahoo! Finance]Yahoo! Finance
- Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Halozyme Therapeutics, Inc. (HALO) Q4 2025 Sales/Trading Call Transcript [Seeking Alpha]Seeking Alpha
HALO
Earnings
- 11/3/25 - Beat
HALO
Sec Filings
- 1/28/26 - Form 8-K
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- HALO's page on the SEC website